AtriCure, Inc.
6033 Schumacher Park Drive
West Chester
Ohio
45069
United States
Tel: 513-755-4100
Fax: 513-755-4108
Website: http://www.atricure.com/
Email: info@atricure.com
327 articles about AtriCure, Inc.
-
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
1/24/2023
AtriCure, Inc. today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.
-
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
1/9/2023
AtriCure, Inc. announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance.
-
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
12/20/2022
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
-
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
11/8/2022
AtriCure, Inc. today announced that the company will present at the 34th Annual Piper Sandler Healthcare Conference.
-
AtriCure Reports Third Quarter 2022 Financial Results
11/1/2022
AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management, announced third quarter 2022 financial results.
-
AtriCure to Participate in Upcoming Investor Conferences - October 25, 2022
10/25/2022
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced that the company will be participating in upcoming investor conferences.
-
AtriCure to Announce Third Quarter 2022 Financial Results
10/11/2022
AtriCure, Inc. today announced that it will release its third quarter 2022 financial results on Tuesday, November 1, 2022.
-
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
9/6/2022
AtriCure, Inc. announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy.
-
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
8/16/2022
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference.
-
AtriCure Reports Second Quarter 2022 Financial Results
8/2/2022
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results.
-
AtriCure to Participate at Upcoming Investor Conferences - July 20, 2022
7/20/2022
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced that the company will be participating in two upcoming investor conferences.
-
AtriCure to Announce Second Quarter 2022 Financial Results
7/12/2022
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on Tuesday, August 2, 2022.
-
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
6/7/2022
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia.
-
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
6/1/2022
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today.
-
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
4/12/2022
AtriCure Launches EnCompass ® Clamp, a part of Isolator Synergy™ Ablation System.
-
AtriCure to Announce First Quarter 2022 Financial Results
4/11/2022
AtriCure, Inc. today announced that it will release its first quarter 2022 financial results on Tuesday, May 3, 2022.
-
AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/1/2022
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in the upcoming 11th Annual SVB Leerink Global Healthcare Conference.
-
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
1/25/2022
AtriCure, Inc. today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022.
-
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022
1/10/2022
AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021 and provided 2022 financial guidance.
-
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
12/20/2021
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference,